Cargando…

ImmunoStart: preparing patients for immunosuppression

OBJECTIVES: Patients with immune-mediated inflammatory disease (IMID) present an increased risk of infection. Here, we present the concept of a preventive consultation called ImmunoStart and the first results of its implementation in the care pathway of patients with IMID. METHODS: Relevant informat...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Charlotte, Muls, Vinciane, Brasseur, Céline, Meric de Bellefon, Laurent, Lam Hoai, Xuan-Lan, Vanderhilst, Jeroen, Delforge, Marc, Di Romana, Silvana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665374/
https://www.ncbi.nlm.nih.gov/pubmed/34909567
http://dx.doi.org/10.1093/rap/rkab092
_version_ 1784613995255169024
author Martin, Charlotte
Muls, Vinciane
Brasseur, Céline
Meric de Bellefon, Laurent
Lam Hoai, Xuan-Lan
Vanderhilst, Jeroen
Delforge, Marc
Di Romana, Silvana
author_facet Martin, Charlotte
Muls, Vinciane
Brasseur, Céline
Meric de Bellefon, Laurent
Lam Hoai, Xuan-Lan
Vanderhilst, Jeroen
Delforge, Marc
Di Romana, Silvana
author_sort Martin, Charlotte
collection PubMed
description OBJECTIVES: Patients with immune-mediated inflammatory disease (IMID) present an increased risk of infection. Here, we present the concept of a preventive consultation called ImmunoStart and the first results of its implementation in the care pathway of patients with IMID. METHODS: Relevant information about vaccination history, tuberculosis exposure and other infectious risks were collected through blood sampling, complete anamnesis, chest X-ray and Mantoux test. During the ImmunoStart consultation, vaccination schedules, specific treatments and risk considerations were discussed. RESULTS: Between October 2016 and February 2020, 437 patients were seen at an ImmunoStart consultation, mainly referred by rheumatologists (56%), dermatologists (25%) and gastroenterologists (18%). A total of 421 (96%) patients needed at least one vaccine (a mean of 3.3 vaccines per patient). Live attenuated vaccine was indicated for 45 patients (10%), requiring them to reduce or interrupt their immunosuppressive drug(s). Ninety-two patients (21%) were treated for latent tuberculosis infection. CONCLUSION: This preventive consultation provides a centralized and systematic setting for the direct management of patients with IMID in need of vaccination, treatment of latent disease and specific advice regarding their immunomodulating treatments.
format Online
Article
Text
id pubmed-8665374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86653742021-12-13 ImmunoStart: preparing patients for immunosuppression Martin, Charlotte Muls, Vinciane Brasseur, Céline Meric de Bellefon, Laurent Lam Hoai, Xuan-Lan Vanderhilst, Jeroen Delforge, Marc Di Romana, Silvana Rheumatol Adv Pract Concise Report OBJECTIVES: Patients with immune-mediated inflammatory disease (IMID) present an increased risk of infection. Here, we present the concept of a preventive consultation called ImmunoStart and the first results of its implementation in the care pathway of patients with IMID. METHODS: Relevant information about vaccination history, tuberculosis exposure and other infectious risks were collected through blood sampling, complete anamnesis, chest X-ray and Mantoux test. During the ImmunoStart consultation, vaccination schedules, specific treatments and risk considerations were discussed. RESULTS: Between October 2016 and February 2020, 437 patients were seen at an ImmunoStart consultation, mainly referred by rheumatologists (56%), dermatologists (25%) and gastroenterologists (18%). A total of 421 (96%) patients needed at least one vaccine (a mean of 3.3 vaccines per patient). Live attenuated vaccine was indicated for 45 patients (10%), requiring them to reduce or interrupt their immunosuppressive drug(s). Ninety-two patients (21%) were treated for latent tuberculosis infection. CONCLUSION: This preventive consultation provides a centralized and systematic setting for the direct management of patients with IMID in need of vaccination, treatment of latent disease and specific advice regarding their immunomodulating treatments. Oxford University Press 2021-11-27 /pmc/articles/PMC8665374/ /pubmed/34909567 http://dx.doi.org/10.1093/rap/rkab092 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Concise Report
Martin, Charlotte
Muls, Vinciane
Brasseur, Céline
Meric de Bellefon, Laurent
Lam Hoai, Xuan-Lan
Vanderhilst, Jeroen
Delforge, Marc
Di Romana, Silvana
ImmunoStart: preparing patients for immunosuppression
title ImmunoStart: preparing patients for immunosuppression
title_full ImmunoStart: preparing patients for immunosuppression
title_fullStr ImmunoStart: preparing patients for immunosuppression
title_full_unstemmed ImmunoStart: preparing patients for immunosuppression
title_short ImmunoStart: preparing patients for immunosuppression
title_sort immunostart: preparing patients for immunosuppression
topic Concise Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665374/
https://www.ncbi.nlm.nih.gov/pubmed/34909567
http://dx.doi.org/10.1093/rap/rkab092
work_keys_str_mv AT martincharlotte immunostartpreparingpatientsforimmunosuppression
AT mulsvinciane immunostartpreparingpatientsforimmunosuppression
AT brasseurceline immunostartpreparingpatientsforimmunosuppression
AT mericdebellefonlaurent immunostartpreparingpatientsforimmunosuppression
AT lamhoaixuanlan immunostartpreparingpatientsforimmunosuppression
AT vanderhilstjeroen immunostartpreparingpatientsforimmunosuppression
AT delforgemarc immunostartpreparingpatientsforimmunosuppression
AT diromanasilvana immunostartpreparingpatientsforimmunosuppression